ரிபேக்க மேக்ஸீ News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ரிபேக்க மேக்ஸீ. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ரிபேக்க மேக்ஸீ Today - Breaking & Trending Today

With new treatments, PET imaging adds valuable information to brain metastasis monitoring


 E-Mail
IMAGE: After radiosurgery concurrent with nivolumab in 59-year-old patient with melanoma BM (patient 1; Supplemental Tables 3 and 5), F-18 FET PET at follow-up 12 weeks after treatment initiation (bottom row).
view more 
Credit: Image created by N. Galldiks et al., Research Center Juelich, Juelich, Germany.
Reston, VA For patients with brain metastases, amino acid positron emission tomography (PET) can provide valuable information about the effectiveness of state-of-the-art treatments. When treatment monitoring with contrast-enhanced magnetic resonance imaging (MRI) is unclear, adding 18F-FET PET can help to accurately diagnose recurring brain metastases and reliably assess patient response. This research was published in The
Journal of Nuclear Medicine. ....

Nordrhein Westfalen , Nicole Kreuzberg , Norbert Galldiks , Gary Ceccon , Karl Josef Langen , Maximilliani Ruge , Cornelia Mauch , Philipp Lohmann , Gereonr Fink , Dianasy Abdulla , Jan Michael Werner , Jennifer Landsberg , Michael Weller , Fabian Wolpert , Maike Trommer , Simone Marnitz , Rebecca Maxey , Max Schlaak , Viola Schweinsberg , Christian Tonn , Martin Kocher , Matthias Scheffler , Christian Baues , Gabriele Stoffels , University Of Cologne , Journal Of Nuclear Medicine ,

Immuno-PET can give physicians early insight into tumor response to targeted therapy


 E-Mail
IMAGE: Three receptor tyrosine kinases (RTKs) EGFR (orange), HER2 (pink), and MET (green) are imaged before and after the use of a MET-selective tyrosine kinase inhibitor (Trametinib), and trametinib, a mitogen activated protein.
view more 
Credit: Image created by Patricia Pereira, PhD, Research Associate at Memorial Sloan Kettering Cancer Center
Reston, VA Immuno-positron emission tomography (PET) imaging can provide early insight into a tumor s response to targeted therapy, allowing physicians to select the most effective treatment for patients who have cancer. The new research was published in the March issue of The
Journal of Nuclear Medicine.
The research showed that immuno-PET successfully visualizes changes in different cancer receptors (receptor tyrosine kinases, or RTKs) within tumors during targeted therapies. This gives physicians a tool that can be used to evaluate the effectiveness of a treatment soon after its administration. ....

New York , United States , National Institutes Of Health , Memorial Sloan Kettering Cancer Center , Jalen Norfleet , Rebecca Maxey , Alice Goodwin , Patricia Pereira , Jason Lewis , Freddye Escorcia , Patriciamr Pereira , Freddy Escorcia , Jasons Lewis , Molecular Imaging Program , Journal Of Nuclear Medicine , Department Of Radiology , National Cancer Institute , Weill Cornell Medical College , Cancer Research , Tumor Ecosystems Center , Society Of Nuclear Medicine , Commonwealth Foundation For Cancer Research , Tow Foundation Postdoctoral Fellowship , Geoffrey Beene Cancer Research Center , Media Center , Clinical Investigator Development Program ,